Introduction: The Right Treatment for the Right Patient
Not everyone who walks through our doors will be an ideal candidate for stem cell therapy — and we believe transparency about this is essential. Our goal is not simply to offer treatment, but to offer transformative results.
The clinical trial evidence consistently shows that patient selection is one of the most important factors determining treatment success. While some meta-analyses of unselected populations show modest overall effects (Dai et al., 2021), [10]proper patient selection based on established criteria dramatically improves outcomes. By carefully evaluating each patient's unique situation, we can:
- Maximize treatment effectiveness for those who are good candidates
- Avoid unnecessary expense for those unlikely to benefit
- Protect patient safety by identifying potential contraindications
- Set realistic expectations based on scientific evidence
This guide explains who tends to respond best to regenerative therapies, who may need additional evaluation, and who may not be suitable candidates at this time.
Ideal Candidates: Who Responds Best?
Joint Conditions (Knee, Hip, Shoulder)
Clinical trials have identified characteristics that predict strong treatment response:
Kellgren-Lawrence Grade 2-3 Osteoarthritis
The Kellgren-Lawrence (K-L) grading system measures joint degeneration severity on a 0-4 scale:
A landmark 2022 systematic review by Daghir-Wojtkowiak et al. analyzing 23 clinical trials involving 1,425 patients demonstrated that stem cell therapy produced significant improvements in pain and function, with the strongest responses observed in K-L grades 2-3. The study found statistically significant improvements in VAS pain scores (mean reduction 2.8 points) and WOMAC function scores (mean improvement 18.5 points) at 12-month follow-up. [4]
Clinical Trial Inclusion Criteria That Predict Success:
Based on analysis of successful Phase I-III trials, ideal orthopedic candidates typically share these characteristics: [1]⁻ [5]
- Age 40-75 years (most studied range)
- K-L grades 1-3 (mild to moderate degeneration)
- BMI < 35 (obesity may reduce treatment effectiveness)
- Chronic symptoms ≥ 6 months (to differentiate from acute injury)
- Failed conservative treatment (physical therapy, NSAIDs, corticosteroid injections)
- Not requiring immediate surgery (no joint instability, loose bodies, or mechanical locking)
Why Moderate Disease Responds Better:
The science suggests that stem cells work primarily through:
- Paracrine signaling — releasing growth factors and anti-inflammatory molecules
- Immunomodulation — calming chronic inflammation
- Tissue homeostasis — supporting the body's natural repair processes
In severely degenerated joints (K-L grade 4), the structural damage may be too extensive for these mechanisms alone to produce dramatic improvement. [6]However, even grade 4 patients may experience meaningful pain relief and improved function — just with more realistic expectations.
Respiratory Conditions (COPD, Pulmonary Fibrosis)
Stem cell therapy for respiratory conditions is earlier in its clinical development compared to orthopedic applications, but emerging evidence suggests promising results for select patients.
Emerging Candidate Criteria:
- COPD Stage II-III (moderate to severe, but not end-stage)
- Stable disease (no exacerbations in past 4-6 weeks)
- Willing to participate in pulmonary rehabilitation
- Non-smoker or committed to smoking cessation
- Adequate cardiac function (heart conditions can complicate assessment)
Important Note: Respiratory applications are considered investigational. Patients should understand that evidence, while encouraging, is less robust than for joint conditions.
Wellness and Anti-Aging Applications
The clinical philosophy emphasizes that "the healthier you are, the better stem cells work." This creates a somewhat paradoxical situation where healthy individuals seeking optimization may be excellent candidates.
Ideal Wellness Candidates:
- Age 45+ seeking proactive health optimization
- No active infections or malignancies
- Stable chronic conditions (well-controlled diabetes, hypertension)
- Realistic expectations — wellness benefits are subtle and gradual
- Commitment to healthy lifestyle (diet, exercise, sleep optimization)
Potential Wellness Benefits (Based on Mechanism of Action):
- Reduced systemic inflammation (a driver of aging)
- Enhanced tissue repair capacity
- Improved metabolic function
- Potential neuroprotective effects
Who May Need Additional Evaluation
Some conditions don't automatically disqualify patients but require careful assessment:
Autoimmune Conditions
Patients with conditions like rheumatoid arthritis, lupus, or psoriatic arthritis present a complex picture:
- Potential benefit: MSCs have immunomodulatory properties that may help regulate overactive immune responses
- Potential concern: Some autoimmune conditions may theoretically interact unpredictably with stem cell therapy
- Our approach: Case-by-case evaluation with rheumatology consultation if needed
A 2018 Phase 1/2 clinical trial specifically studied patients with rheumatoid arthritis and knee involvement, finding that intra-articular MSC injection was safe and produced clinical improvement. [7]
Diabetes
Well-controlled diabetes is generally not a contraindication:
- HbA1c < 8.0% — typically acceptable
- HbA1c 8.0-9.0% — requires optimization before treatment
- HbA1c > 9.0% — treatment postponed until better control achieved
Poorly controlled diabetes impairs healing and may reduce treatment effectiveness. Additionally, patients with diabetic neuropathy may have altered pain perception that complicates outcome assessment.
Obesity (BMI > 35)
Higher BMI may reduce treatment effectiveness through several mechanisms:
- Increased mechanical joint loading
- Chronic low-grade inflammation associated with adipose tissue
- Altered pharmacokinetics and cell distribution
- Reduced physical activity limiting rehabilitation
Our approach: We don't automatically exclude patients with higher BMI but set realistic expectations and strongly encourage weight management as part of the treatment plan.
Previous Joint Surgery
Prior surgical procedures require individual assessment:
Current Medication Use
Certain medications may interact with stem cell therapy:
- NSAIDs — Should be discontinued 1 week before treatment
- Corticosteroids — May need to be held or tapered before treatment
- Immunosuppressants — Require careful evaluation (may affect MSC function)
- Anticoagulants — May need temporary adjustment for injection procedures
Who Is NOT a Candidate
Some conditions are absolute or relative contraindications:
Absolute Contraindications
Active Malignancy
Patients with known active cancer should not receive stem cell therapy outside of oncology-specific protocols. [6]
- Rationale: While MSCs themselves are not tumorigenic, their growth factor secretion could theoretically support tumor growth
- Exception: Patients in remission (typically 5+ years) may be considered on a case-by-case basis with oncologist clearance
Active Systemic Infection
Treatment should be postponed until infection is resolved:
- Rationale: MSCs modulate immune function; active infection requires full immune response
- Includes: Active bacterial infections, acute viral illness, uncontrolled chronic infections
Pregnancy or Nursing
Stem cell therapy is not recommended during pregnancy or while breastfeeding due to insufficient safety data.
Relative Contraindications (Case-by-Case)
Severe Immunodeficiency
Patients with severe immune compromise require careful evaluation:
- HIV/AIDS with low CD4 counts
- Patients on high-dose immunosuppression
- Primary immunodeficiency disorders
Bleeding Disorders
Uncontrolled coagulopathy may increase procedural risks.
Unrealistic Expectations
Perhaps the most important "contraindication" is unrealistic expectations. Patients who:
- Expect immediate, complete pain resolution
- Refuse to participate in rehabilitation
- Are seeking a "magic cure" without lifestyle changes
- Cannot accept any possibility of limited benefit
...may not be good candidates, regardless of their medical suitability.
The Dose Makes the Difference: Why Cell Count Matters
Clinical trial evidence consistently demonstrates a dose-response relationship in stem cell therapy:
Evidence for High-Dose Protocols
Lamo-Espinosa et al. (2016) — Phase I/II Randomized Controlled Trial [3]
Compared high-dose (100 × 10⁶) vs. low-dose (10 × 10⁶) bone marrow MSCs plus hyaluronic acid vs. hyaluronic acid alone in 30 patients:
Key Finding: Only the high-dose group showed objective structural improvement on MRI.
Jo et al. (2017) — 2-Year Follow-Up [8]
Following 18 patients treated with low, medium, or high-dose (1 × 10⁸) adipose-derived MSCs:
- High-dose group: Maintained clinical improvements through 2 years
- Low/medium-dose groups: Improvements deteriorated after 12 months
Kim et al. (2022) — 5-Year Follow-Up [2]
Eleven patients treated with high-dose (1.0 × 10⁸) adipose-derived MSCs:
- No treatment-related adverse events through 5 years
- Clinical improvements maintained throughout follow-up
- Structural improvements (WORMS scores) significant up to 3 years
Lu et al. (2019) — Phase IIb Randomized Controlled Trial [9]
A prospective, double-blind trial of autologous adipose-derived MSCs for knee osteoarthritis confirmed both safety and efficacy of intra-articular MSC injection, supporting the dose-response relationship observed in earlier studies.
Our Protocol Rationale
Based on this evidence, our standard protocol utilizes:
- Day 1: Blood panel + Exosomes + NAD+ (assessment and preparation)
- Day 2: Bloodwork results review + physician consultation + package decision
- Day 2-3: 50 million umbilical cord-derived MSCs per session (the "hero" treatment); advanced cases receive a second 50M session on Day 5-6
This high-dose allogeneic approach provides:
- ✅ Sufficient cell numbers for therapeutic effect
- ✅ Young, potent cells (not affected by patient age)
- ✅ No additional procedure for cell harvesting
- ✅ Immediate treatment (no culture period)
Our Assessment Process
Step 1: Initial Screening
Before traveling to the clinic, all people considering treatment complete:
- Medical history questionnaire
- Current imaging review (X-rays, MRI if available)
- Medication list review
- Virtual consultation with the medical team
This allows us to identify obvious contraindications and set appropriate expectations before any commitment.
Step 2: In-Clinic Evaluation
Upon arrival at our Bangkok clinic:
- Comprehensive physical examination
- Blood panel (including inflammatory markers, blood counts, metabolic panel)
- Updated imaging if needed
- Detailed discussion of goals, expectations, and realistic outcomes
Step 3: Personalized Treatment Plan
Based on the evaluation, we develop an individualized plan that may include:
- Core treatment (MSC infusion, dose and delivery route)
- Adjunctive therapies (exosomes, NAD+, PRP as appropriate)
- Rehabilitation protocol
- Follow-up schedule
Frequently Asked Questions
"I'm 72 years old. Am I too old for stem cell therapy?"
No. Age alone is not a disqualifying factor. Clinical trials have enrolled patients up to age 75 with excellent results. [8]What matters more than chronological age is:
- Overall health status
- Disease severity
- Presence of comorbidities
- Functional goals
By using allogeneic (donor) umbilical cord-derived cells, patient age does not affect cell quality — you receive young, potent cells regardless of your age.
"My doctor says I have bone-on-bone arthritis. Can stem cells help?"
Possibly, but with realistic expectations. Severe (K-L grade 4) osteoarthritis shows less robust responses in clinical trials compared to moderate disease. [4]However:
- Many patients still experience meaningful pain reduction
- Some delay joint replacement surgery
- Quality of life may improve even without complete symptom resolution
A thorough evaluation can help determine if treatment is likely to provide sufficient benefit for your situation.
"I had a cortisone injection last month. Do I need to wait?"
Yes. We typically recommend waiting 4-6 weeks after corticosteroid injection before stem cell therapy. Corticosteroids may:
- Temporarily suppress local immune function
- Potentially affect MSC survival and function
- Confound early outcome assessment
"What if I'm not a good candidate for stem cell therapy?"
We believe in honest assessment. If our evaluation suggests you're unlikely to benefit significantly from stem cell therapy, we will tell you. Options may include:
- Addressing modifiable factors (weight loss, smoking cessation, medication optimization) and reassessing later
- Alternative treatments that may be more appropriate for your condition
- Referral for surgical evaluation if indicated
Our reputation depends on successful outcomes, and that starts with selecting the right patients.
"How do I know if my expectations are realistic?"
Realistic expectations include:
✅ Realistic:
- Significant pain reduction (most patients achieve 30-70% improvement)
- Improved function and mobility
- Possible delay or avoidance of surgery
- Gradual improvement over weeks to months
- Benefits lasting 1-5 years (varies by individual)
❌ Unrealistic:
- Complete elimination of all symptoms
- Immediate results
- Guaranteed outcome
- Regeneration of completely destroyed cartilage
- Elimination of need for any other treatment
Conclusion
Stem cell therapy offers genuine hope for many patients with chronic pain and degenerative conditions — but it's not a universal solution. The most successful outcomes come from matching the right treatment to the right patient.
If you're wondering whether you might be a candidate, we encourage you to reach out for an initial consultation. Our team can review your medical history, imaging, and goals to provide an honest assessment of whether our treatments are likely to help you achieve the transformation you're seeking.
Remember: The best outcomes happen when science guides patient selection.